TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12850889
Drug: Placebo drink
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo drink (450 ml/day for 4 weeks)
Study: 9235072
Drug: Weight loss
Normalized name: HERBAL WEIGHT LOSS AID
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weight loss and exercise intervention (12 weekly group sessions, 1 individual counseling session, 6 biweekly follow-up sessions)
Study: 1662884
Drug: Temafloxacin 400
Normalized name: temafloxacin 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Temafloxacin 400 mg b.i.d. for 28 days
Study: 31358540
Drug: Atezolizumab 0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atezolizumab 0.1 to 20 mg/kg or ≥10 mg/kg every 3 weeks
Study: 17392697
Drug: Low‐fat (15%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low‐fat (15% fat), high‐fiber (18 g/1000 kcal) diet supplemented with 40 g soy protein isolate (n=26)
Study: 10804328
Drug: 20% Intralipid
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20% Intralipid (60 ml/h) and heparin (900 U/h) for 5.5 h
Study: 20655660
Drug: Conventional conservative
Normalized name: Conserved dopamine neurotrophic factor
DrugBank: HER-902 (DB17948)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional conservative orthopaedic treatment (COT)
Study: 17717682
Drug: Alcohol in
Normalized name: WATER/BENZYL ALCOHOL INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alcohol in juice (1.4 g/l)
Study: 15758565
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg intravenous dexamethasone suppression test
Study: 12036821
Drug: Calcium (1450
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium (1450 mg/d) and vitamin D (10 microg (400 IU)/d)
Study: 12036821
Drug: Calcium, vitamin
Normalized name: Vitamin B1 with Calcium, Vitamin B1 with Calcium oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium, vitamin D, and other nutrients (multinutrient supplement)
Study: 10208191
Drug: Albuterol via
Normalized name: Albuterol
DrugBank: Albuterol (DB01001)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albuterol via Clickhaler (DPI) at 200 microg inhaled at 15 L/min
Study: 10208191
Drug: Albuterol via
Normalized name: Albuterol
DrugBank: Albuterol (DB01001)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albuterol via Clickhaler (DPI) at 200 microg inhaled at 30 L/min
Study: 10208191
Drug: Albuterol via
Normalized name: Albuterol
DrugBank: Albuterol (DB01001)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albuterol via Clickhaler (DPI) at 200 microg inhaled at 60 L/min
Study: 10208191
Drug: Albuterol via
Normalized name: Albuterol
DrugBank: Albuterol (DB01001)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albuterol via pMDI inhaled at 30 L/min
Study: 1844749
Drug: Diuretics alone
Normalized name: hydralazine hydrochloride / hydrochlorothiazide / reserpine Oral Tablet [Diuretic Ap-Es]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diuretics alone (23%)
Study: 1844749
Drug: Beta blockers
Normalized name: BETA BLOCKERS/RELATED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta blockers alone (32%)
Study: 1844749
Drug: Diuretic and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diuretic and beta blocker (38%)
Study: 1844749
Drug: Combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy with vasodilators (9%)
Study: 1844749
Drug: Other forms
Normalized name: Ether
DrugBank: Diethyl ether (DB13598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other forms of therapy (5%)
Study: 31428433
Drug: Behaviour change
Normalized name: monofluorophosphate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behaviour change intervention (delivered over eight sessions as weekly one‐on‐one, face‐to‐face 40‐min consultations)
Study: 31428433
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care (pharmacological treatment and similar educational programmes)
Study: 29871085
Drug: Reposition plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reposition plus drug treatment (Barbecue reposition maneuver + Alprostadil, Cinepazide, Betahistine)
Study: 29871085
Drug: Reposition plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reposition plus drug treatment
Study: 20854342
Drug: Foot massage
Normalized name: MENTHOL 13.5 mg in 1 mL TOPICAL LOTION [Foot Works Achy Foot Massager Pain Relieving]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Foot massage (20 min daily for 5 days)
Study: 17983871
Drug: Budesonide inhalation
Normalized name: Budesonide Inhalation Powder
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Budesonide inhalation suspension 0.5 mg once daily
Study: 17983871
Drug: Montelukast 4
Normalized name: montelukast 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Montelukast 4 or 5 mg once daily
Study: 16027500
Drug: Hand-Acupuncture therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hand-Acupuncture therapy for 20 minutes
Study: 6873004
Drug: Social alcohol
Normalized name: Alcohol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Social alcohol intake (1-3 glasses of vodka mixed with orangeade, consumed twice a week for 16 weeks)
Study: 24719139
Drug: ALN/D5600 (alendronate
Approvals — FDA: no, EMA: no, PMDA: no
Description: ALN/D5600 (alendronate 70 mg + 5600 IU vitamin D₃)
Study: 24719139
Drug: ALN (alendronate
Approvals — FDA: no, EMA: no, PMDA: no
Description: ALN (alendronate 70 mg without additional vitamin D)
Study: 23767196
Drug: Octreotide (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Octreotide (100 microgram stat) along with fluid and antibiotics
Study: 23767196
Drug: Racecadotril (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Racecadotril (1.5 mg/kg three times a day) along with fluid and antibiotics
Study: 23767196
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group received only fluids and antibiotics
Study: 19395036
Drug: Prior glaucoma
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prior glaucoma surgery with preoperative glaucoma medication use
Study: 17848840
Drug: Continuous subcutaneous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous subcutaneous insulin infusion (CSII) with aspart or lispro insulin
Study: 17848840
Drug: Multiple daily
Normalized name: Multivitamin Oral Tablet [MULTIPLE DAILY W/BETA]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple daily injections (MDI) with once-daily glargine and human regular insulin at meals
Study: 9862252
Drug: Irbesartan 25
Normalized name: Hydrochlorothiazide/Irbesartan 25 MG-300 MG Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irbesartan 25 mg capsules (two capsules after a 10 h fast)
Study: 7650233
Drug: Td vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Td vaccine alone (group 1)
Study: 7650233
Drug: Td vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Td vaccine plus 500 IU of TIG (group 2)
Study: 805518
Drug: Aqueous solution
Normalized name: Zephiran Chloride 1:750 Antiseptic Aqueous Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aqueous solution of pteroylglutamic acid
Study: 22672107
Drug: Cilostazol (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cilostazol (100 mg daily)
Study: 22672107
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (Aspirin 100 mg or Clopidogrel 50 mg‐75 mg daily)
Study: 21663422
Drug: Lithium 300
Normalized name: lithium 300 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lithium 300 mg twice daily (Arm I)
Study: 21663422
Drug: Lithium 300
Normalized name: lithium 300 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lithium 300 mg thrice daily (Arms II and III)
Study: 21663422
Drug: Lithium treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lithium treatment (all arms)
Study: 16965240
Drug: Combination low
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination low fat, high FV
Study: 11151749
Drug: Ciprofloxacin 250
Normalized name: ciprofloxacin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacin 250 mg twice daily for 7 days
Study: 3704451
Drug: Methylphenidate (10,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylphenidate (10, 30, or 60 mg/day)
Study: 3704451
Drug: Pemoline (18.75,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pemoline (18.75, 56.25, or 112.5 mg/day)
Study: 3704451
Drug: Protriptyline (10,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protriptyline (10, 30, or 60 mg/day)
Study: 25005346
Drug: Fixed Tc-99m-tetrofosmin
Normalized name: Tc-99m tetrofosmin
DrugBank: Technetium Tc-99m tetrofosmin (DB09160)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed Tc-99m-tetrofosmin tracer dose
Study: 25005346
Drug: Body weight-dependent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Body weight-dependent tracer dose and scan time
Study: 21495052
Drug: Behavioral family
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavioral family therapy (BFT) plus fluoxetine
Study: 21495052
Drug: Behavioral family
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavioral family therapy (BFT) plus placebo
Study: 21495052
Drug: Systems family
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systems family therapy (SFT) plus fluoxetine
Study: 21495052
Drug: Systems family
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systems family therapy (SFT) plus placebo
Study: 18978102
Drug: Mifepristone 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mifepristone 5 mg
Study: 8984147
Drug: Troxerutin 3,500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Troxerutin 3,500 mg
Study: 8984147
Drug: Troxerutin 1,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Troxerutin 1,000 mg twice daily
Study: 1837496
Drug: Acute verapamil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acute verapamil administration (160 mg)
Study: 1837496
Drug: Chronic verapamil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chronic verapamil treatment (240 mg/day for 12 months)
Study: 6122652
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg flunitrazepam orally the night before operation and 1 mg on the morning of operation (group 1)
Study: 6122652
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg pentobarbital orally the night before operation, followed by intramuscular scopolamine (0.006 mg/kg) + morphine (0.02 mg/kg) on the morning of operation (group 2)
Study: 28844361
Drug: Internet-based cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet-based cognitive therapy
Study: 21371164
Drug: Formulated Collagen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formulated Collagen Gel (FCG)
Study: 19835120
Drug: Nitramisole cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitramisole cream (NC)
Study: 17907004
Drug: Micronized estradiol
Normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Micronized estradiol 2 mg/day
Study: 17907004
Drug: Micronized estradiol
Normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Micronized estradiol 2 mg/day plus norethisterone acetate 1 mg/day
Study: 12040360
Drug: Terbogrel (thromboxane
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terbogrel (thromboxane synthetase inhibitor and receptor antagonist) for 12 weeks
Study: 9873846
Drug: Asserachrom VIII:CAg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Asserachrom VIII:CAg ELISA using monoclonal antibodies (MoAbs 833 and D4H1)
Study: 8848535
Drug: Lorazepam (1.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lorazepam (1.2 mg)
Study: 688767
Drug: Topical clotrimazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical clotrimazole (Lotrimin)
Study: 688767
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of ultramicrosize griseofulvin and topical clotrimazole
Study: 25994853
Drug: Erlotinib administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erlotinib administered 2 hours after a meal
Study: 25994853
Drug: Erlotinib administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erlotinib administered in complete fasting
Study: 24152604
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg empagliflozin under fasted conditions
Study: 24152604
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg empagliflozin after a high‐fat, high‐calorie breakfast
Study: 24152604
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg empagliflozin under fasted conditions
Study: 14969628
Drug: Carbon-coated stents
Normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Carbon-coated stents (CC)
Study: 11355930
Drug: Granulocyte-macrophage (GM)-CSF
Normalized name: Granulocyte macrophage-colony stimulating factor
DrugBank: Molgramostim (DB12525)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Granulocyte-macrophage (GM)-CSF or Granulocyte (G)-CSF
Study: 11355930
Drug: Cytokines (e.g.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cytokines (e.g. pegylated recombinant human megakaryocytic growth and development factor + G- or GM-CSF)
Study: 11355930
Drug: Therapies targeting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapies targeting cytokine receptors on AML blasts
Study: 9153103
Drug: EPO administration
Normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: EPO administration (120 U/kg per week for 5 to 8 months)
Study: 26222158
Drug: Channa striatus
Normalized name: Labrus striatus flesh
DrugBank: Black sea bass (DB15547)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Channa striatus extract (500 mg daily for six weeks)
Study: 26222158
Drug: Placebo (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (500 mg maltodextrin daily for six weeks)
Study: 21967936
Drug: Rapid maxillary
Normalized name: Abreva Rapid Pain Relief
DrugBank: Glycerin (DB09462)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rapid maxillary expansion and facemask therapy
Study: 16646643
Drug: Oral hygiene
Normalized name: HYDROGEN PEROXIDE 2.94 mL in 2.94 mL ORAL SPRAY [OROXID Forte Oral Hygiene]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral hygiene protocol managed by a dental hygienist
Study: 14608343
Drug: no decontamination
Approvals — FDA: no, EMA: no, PMDA: no
Description: no decontamination therapy
Study: 8922008
Drug: Intermittent nebulized
Normalized name: Hydra-Neb
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent nebulized (IN) albuterol (0.15 mg/kg/dose every 30 min)
Study: 8922008
Drug: Continuous nebulized
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous nebulized (CN) albuterol (0.3 mg/kg/hr)
Study: 8922008
Drug: Continuous nebulized
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous nebulized (CN) albuterol
Study: 8922008
Drug: Intermittent nebulized
Normalized name: Hydra-Neb
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent nebulized (IN) albuterol
Study: 3919415
Drug: Second-line anti-rheumatic
Normalized name: Anti Bac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Second-line anti-rheumatic drugs (e.g., gold) continuously for 12 months
Study: 27485930
Drug: Cognitive Behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioral Group Therapy for elderly with Type 2 diabetes and minor depression
Study: 24810476
Drug: Taikong Yangxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Taikong Yangxin Prescription (TYP)
Study: 19955769
Drug: Cold-blood cardioplegia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cold-blood cardioplegia enriched with N-acetylcysteine (NAC) (50 mg/kg)
Study: 18703004
Drug: Ustekinumab 27
Normalized name: Ustekinumab
DrugBank: Ustekinumab (DB05679)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ustekinumab 27 mg
Study: 18703004
Drug: Ustekinumab 90
Normalized name: ustekinumab 90 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ustekinumab 90 mg q8w
Study: 18703004
Drug: Ustekinumab 180
Normalized name: Ustekinumab
DrugBank: Ustekinumab (DB05679)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ustekinumab 180 mg
Study: 8832600
Drug: Three 20-micrograms
Normalized name: THREE-LOBE SAGE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three 20-micrograms doses at 0, 1, and 2 months (group II)
Study: 8832600
Drug: Three 20-micrograms
Normalized name: THREE-LOBE SAGE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three 20-micrograms doses at 0, 1, and 6 months (group III)
Study: 8832600
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose schedule of three 10-micrograms doses at 0, 1, and 2 months (group I)
Study: 1596903
Drug: Control patients
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control patients (not treated with the autologous colon tumor vaccine)
Study: 25292404
Drug: Fructo-oligosaccharides (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fructo-oligosaccharides (20 g daily for 30 days)
Study: 24874483
Drug: Exemestane 25
Normalized name: exemestane 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exemestane 25 mg day(-1) + Celecoxib 800 mg day(-1)
Study: 24874483
Drug: Exemestane 25
Normalized name: exemestane 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exemestane 25 mg day(-1)
Study: 11215733
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg [13C]urea + Ensure
Study: 11215733
Drug: 75 mg
Normalized name: talc 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 mg [13C]urea + citric acid
Study: 9124988
Drug: Piperacillin/tazobactam (P/T)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piperacillin/tazobactam (P/T) administered as 30‐minute intravenous infusions 4 or 3 times a day for 3 to 13 days
Study: 3088662
Drug: Oral scopolamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral scopolamine 0.15 mg
Study: 3088662
Drug: Oral scopolamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral scopolamine 0.3 mg
Study: 3088662
Drug: Oral scopolamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral scopolamine 0.6 mg
Study: 3088662
Drug: Oral scopolamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral scopolamine 1.2 mg
Study: 3088662
Drug: Transdermal scopolamine
Normalized name: Transderm Scop
DrugBank: Scopolamine (DB00747)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal scopolamine and higher oral dose conditions
Study: 3088662
Drug: Transdermal scopolamine
Normalized name: Transderm Scop
DrugBank: Scopolamine (DB00747)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal scopolamine patch
Study: 31366300
Drug: Phenylephrine dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenylephrine dose
Study: 29589820
Drug: UC+TxtM (usual
Approvals — FDA: no, EMA: no, PMDA: no
Description: UC+TxtM (usual care plus twice-daily diabetes self-management text messages)
Study: 28665051
Drug: Veliparib 400
Normalized name: veliparib
DrugBank: Veliparib (DB07232)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Veliparib 400 mg
Study: 28665051
Drug: Veliparib 200
Normalized name: veliparib
DrugBank: Veliparib (DB07232)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Veliparib 200 mg
Study: 25752115
Drug: Tympanic injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tympanic injection of triamcinolone acetonide, administered 1 hour before radiotherapy, once a week for 1-7 weeks (treatment group I)
Study: 25752115
Drug: Tympanic injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tympanic injection of triamcinolone acetonide, administered 1 hour before radiotherapy, once a week for 1-12 weeks (treatment group II)
Study: 25752115
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no tympanic injection of triamcinolone acetonide)
Study: 14520857
Drug: Thyroxine (TX)
DrugBank: Levothyroxine (DB00451)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Thyroxine (TX) 75-150 mcg/day
Study: 14520857
Drug: Potassium Iodide
Normalized name: Potassium Iodide
DrugBank: Potassium Iodide (DB06715)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Potassium Iodide (PI) 200 mcg/day
Study: 8882258
Drug: Ondansetron 4
Normalized name: ondansetron 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ondansetron 4 mg at induction of anaesthesia, repeated 8 h later
Study: 31120108
Drug: Automated matched
Approvals — FDA: no, EMA: no, PMDA: no
Description: Automated matched saline infusion with urine output (active group)
Study: 26509681
Drug: Wireless patch
Normalized name: careless weed pollen extract
DrugBank: Amaranthus palmeri pollen (DB10459)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wireless patch
Study: 26509681
Drug: Wired dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wired dose controller
Study: 26509681
Drug: Active treatment
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active treatment (Wireless patch and Wired dose controller)
Study: 23417645
Drug: Postoperative inpatient
Normalized name: Impatiens irvingii whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative inpatient exercise program (twice daily exercise including stretching, core, balance, and low-intensity resistance exercises)
Study: 24499517
Drug: Once-daily insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily insulin detemir
Study: 18945928
Drug: Twice-daily insulin
Normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Twice-daily insulin detemir
Study: 16014056
Drug: Initial statin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Initial statin treatment
Study: 7138748
Drug: Non-steroidal anti-inflammatory
Normalized name: Non-steroidal anti-inflammatory agent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-steroidal anti-inflammatory drugs (NSAID), given three times daily for a week.
Study: 7138748
Drug: NSAID treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: NSAID treatment (specific drugs not detailed), randomized order of administration.
Study: 31800960
Drug: Topical cyclosporine
Normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical cyclosporine A (CsA) 0.05% for 4 weeks
Study: 31800960
Drug: Topical diquafosol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical diquafosol tetrasodium (DQS) 3% for 4 weeks
Study: 27885751
Drug: Cardiac Resynchronization
Normalized name: Leonurus cardiaca extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cardiac Resynchronization Therapy with Defibrillation (CRT-D)